BARD1 Life Sciences Ltd (ASX:BD1) (BARD1 or the Company) is a leading Australian-based medical diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on the development and commercialisation of best in class lifesaving diagnostic solutions for health care professionals and patients. The cancer diagnostics portfolio includes the marketed hTERT test to aid in the diagnosis of bladder cancer and tests in development for ovarian, breast, lung, prostate and pancreatic cancers.


“The Company’s technologies include the BARD1 biomarker technology, hTERT ICC assay, SIEN-NET biomarker capture platform and Sub-B2M pan-cancer probe creating a powerful growth engine to develop in-house and partnered diagnostic and therapeutic products with the potential to generate sustainable product and licensing revenues”


“The Company has a cancer diagnostics portfolio of marketed and development-stage products for multiple cancer indications”